Current cancer immunotherapies often face challenges due to tumor-induced barriers that limit the efficacy and durability of immune cell responses. These barriers prevent immune cells from effectively infiltrating and eliminating tumors, leading to treatment resistance and disease progression.

OverT Bio engineers cell therapies with novel genetic modifications designed to overcome tumor-induced barriers and enhance immune cell function within the tumor microenvironment. By modifying immune cells, OverT Bio aims to improve their ability to recognize, infiltrate, and destroy cancer cells, leading to more effective and durable anti-tumor responses. This approach seeks to create a new generation of immunotherapies that can address the limitations of existing treatments and provide long-term benefits for patients with cancer. The company focuses on developing cell therapies that can persist and function effectively even in the face of immunosuppressive signals from the tumor.

Novel genetic modifications to enhance immune cell infiltration into tumors

Engineered cell therapies designed to overcome tumor-induced immunosuppression

Enhanced recognition and killing of cancer cells by modified immune cells

Development of durable and long-lasting anti-tumor responses

OverT Bio's primary target audience includes cancer patients who are not responding to current immunotherapies, as well as oncologists and researchers seeking more effective and durable treatment options.